Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page revision updated from v3.2.0 to v3.3.2, indicating a minor update to the study record. This change does not modify the study details or enrollment information.SummaryDifference0.0%

- Check26 days agoChange DetectedThe government funding and operating status notice was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check41 days agoChange DetectedNo additions or deletions were detected on the page; the content appears unchanged between versions.SummaryDifference0.4%

- Check69 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference4%

- Check76 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check91 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' link was removed.SummaryDifference0.2%

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.